Safety analysis of an open label, randomized phase 2 study of osimertinib alone versus osimertinib plus carboplatin-pemetrexed for patients with non–small cell lung cancer (NSCLC) that progressed during prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and which harbors a T790M mutation of EGFR.

Abstract

e21073Background: Osimertinib is a standard treatment for patients with NSCLC positive for activating and T790M mutations of EGFR after failure of prior EGFR-TKI treatment. The efficacy and safety ...